Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians.
Level 5 - mechanism / opinion, no new human data
Narrative review summarizing preclinical literature and an uncontrolled case series without systematic review methodology.
PubMed 41476424 · doi:10.1177/03635465251357593
What was done
The authors conducted a narrative review of PubMed literature to evaluate biochemical and clinical evidence for popular injectable peptides in orthopaedics, sports performance, and regenerative medicine, focusing on BPC-157, TB-4, TB-500, CJC-1295 combined with ipamorelin, tesamorelin, and GHK-Cu.
What was found
The abstract reports no quantitative values or statistical metrics. Qualitatively: BPC-157 demonstrated tendon and muscle repair in preclinical models, but human data was limited to a single uncontrolled, methodologically flawed case series reporting improved knee pain; TB-4 and TB-500 promoted tissue repair and angiogenesis in animal models but lack human orthopaedic data and are banned in sports; CJC-1295 plus ipamorelin improved tetanic tension exclusively in murine models; tesamorelin had no orthopaedic evidence; and GHK-Cu lacked clinical musculoskeletal data. Established clinical indications, dosing, frequency, and treatment duration remain completely undefined.
Why it matters
This paper clarifies that despite heavy marketing and public interest in peptide therapies for sports injuries, there is an absence of clinical trial evidence supporting their efficacy or safety in orthopaedics.
Limits
The review is narrative rather than systematic, leaving search parameters, inclusion criteria, and total study count unspecified in the abstract. The underlying evidence base consists almost entirely of animal or bench models, with human data restricted to one low-quality case series.
Cited by
- partial BPC accelerates injury recovery and connective tissue healing by acting on growth factors.